April 22, 2022 Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis read article
April 4, 2022 Quanterix’ Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Disease Activity in Multiple Sclerosis (MS) Patients read article